(P024) Predictors of Radiation-Induced Skin Toxicity: Data From a Prospective Cohort Receiving Breast Radiation

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In this prospectively followed cohort of breast cancer patients receiving RT to the intact breast, novel predictors for more severe skin toxicity were identified, including PR-negative status, invasive ductal histology, and receipt of chemotherapy, as well as known risk factors, including BMI and fractionation scheme.

Jean Wright, MD, Cristiane Takita, MD, Isildinha M. Reis, Wei Zhao, MD, BS, Eunkyung Lee, MS, Jennifer Hu, PhD; Johns Hopkins University; University of Miami

PURPOSE/OBJECTIVES: Breast radiation (RT) is generally well tolerated, but acute skin toxicity is a common side effect that can impact receipt of treatment and quality of life. We sought to identify predictors of radiation-induced skin toxicity in a racially and ethnically diverse cohort of women receiving RT to the intact breast.

MATERIALS AND METHODS: We evaluated the first 392 patients in an ongoing prospective study assessing radiation-induced skin toxicity in patients receiving breast RT. We recorded patient demographics, body mass index (BMI), and disease and treatment characteristics. Skin toxicity grade using Common Terminology Criteria for Adverse Events (CTCAE) and a modified scale capturing moist desquamation were captured at Week 3 and at RT completion. Logistic regression analyses were conducted to evaluate the effect of potential predictors on the risk of skin toxicity.

RESULTS: A total of 20.2% self-identified as African American, 15% self-identified as non-Hispanic white, 61.5% self-identified as Hispanic white, and 3.3% self-identified as other. Mean age was 56.2 years, and 74.2% had a body mass index (BMI) ≥ 25. Disease was stage 0 in 20.2% (in situ), I in 49.2%, and II or III in 30.6%. Further, 17.2% of patients were treated with hypofractionated regimens to the breast +/− regional nodes with a whole-breast dose of < 45 Gy, and 82.8% of patients were treated with conventionally fractionated regimens with a dose of ≥ 45 Gy. On multivariate analysis, both scales identified higher BMI, higher disease stage, invasive ductal histology, progesterone receptor (PR)-negative status, and conventionally fractionated regimens with total radiation dose ≥ 45 Gy as predictors for higher skin toxicity grade. The modified scale also identified larger breast volume as a predictor for moist desquamation, and the CTCAE scale identified chemotherapy use as a predictor for grade 2/3 skin toxicity.

CONCLUSION: In this prospectively followed cohort of breast cancer patients receiving RT to the intact breast, novel predictors for more severe skin toxicity were identified, including PR-negative status, invasive ductal histology, and receipt of chemotherapy, as well as known risk factors, including BMI and fractionation scheme.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content